These results suggest a potential use of EVs as platforms for NIS transfer in radioiodine-based therapies on cancers which are currently resistant to radioiodine, or cancer cells that do not express NIS or which have reduced expression of NIS, thus improving anti-cancer treatment [59]. Here, SLC5A5 is linked to cancer.